Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

Classic serotonergic psychedelics (5-HT2A receptor-mediated compounds such as psilocybin and LSD) have shown promising effects in mood and substance use disorders, but their primary therapeutic mechanisms remain unclear. Prior theoretical accounts have emphasised either neurobiological processes (for example, enhanced plasticity or reopening of critical-period-like windows) or psychological/subjective mechanisms (for example, mystical-type experiences, insight, psychological flexibility, and emotional breakthrough). Few frameworks have successfully integrated these levels of analysis, and existing neurobiological proposals lack specificity about which brain circuits and behaviours they target and how such changes map onto durable clinical benefit. This paper proposes that reversal of, and resilience against, learned helplessness could be a core transdiagnostic mechanism through which classic psychedelics exert therapeutic effects. The authors argue that the learned helplessness paradigm is well suited to bridge preclinical and clinical levels of analysis because it is robust across mammalian species, has well-described neural circuitry, and captures behavioural features that overlap with depressive and stress-related disorders. They set out to synthesise evidence from animal models, neurophysiology, imaging, and limited behavioural pharmacology to show congruence between the neural substrates of learned helplessness and the known effects of classic psychedelics, and to make the case for using learned helplessness as a productive model in future psychedelic research.

The extracted text does not report a formal methods section or a systematic search strategy; the paper is a narrative/theoretical review and hypothesis piece rather than an empirical trial or systematic meta-analysis. The study approach, as presented, consists of literature synthesis and conceptual integration across multiple evidence streams: preclinical rodent experiments (behavioural paradigms, optogenetics, pharmacology, molecular markers), human neuroimaging studies, and clinical trial outcomes for psilocybin and related compounds. Sources examined include classic learned helplessness experiments and mechanistic studies delineating the ventromedial prefrontal cortex (vmPFC) to dorsal raphe nucleus (DRN) circuit, studies of serotonergic receptor pharmacology (notably 5-HT1A and 5-HT2A receptors), preclinical assessments of neural plasticity (spinogenesis, neuritogenesis, synaptic proteins, and activity-dependent gene markers such as c-fos), and behavioural tests commonly used in rodents (active avoidance/shuttlebox, forced swim test, sucrose preference, tail suspension). The authors also draw on clinical paradigms that model aspects of helplessness in humans (for example, inescapable aversive tones or unsolvable puzzles) and on clinical trial evidence for antidepressant effects of psychedelics. No explicit inclusion/exclusion criteria, databases searched, date ranges, or formal risk-of-bias assessments are reported in the extracted text. Analytic methods consist of qualitative synthesis and comparison of circuit-level and behavioural findings to assess whether learned helplessness offers a coherent mechanistic framework for psychedelic action.

Learned helplessness is characterised behaviourally by failure to escape an aversive but controllable situation after prior exposure to inescapable stress, and it has been reliably replicated across species. Mechanistically, the phenomenon has been linked to activation and sensitisation of serotonergic neurons in the dorsal raphe nucleus (DRN), which project to regions including the periaqueductal gray (PAG) and amygdala: DRN-driven serotonin release in the PAG inhibits escape behaviour (promoting passivity), whereas in the amygdala serotonin potentiates fear and anxiety. Detection of control recruits a vmPFC-to-DRN circuit that inhibits DRN activity via GABAergic interneurons, enabling active coping and producing a persistent ‘‘immunization’’ or resilience against later uncontrollable stress. The authors report several overlaps between this helplessness circuitry and psychedelic effects. Classic psychedelics have been shown to modulate DRN activity, often inhibiting DRN firing; this may occur via 5-HT1A autoreceptor activation on DRN neurons or indirectly via 5-HT2A-mediated activation of GABAergic interneurons that suppress DRN output. Psychedelics also activate the prefrontal cortex, including the vmPFC, and enhance cortical glutamate release and measures of plasticity: increases in spinogenesis, neuritogenesis, synapse number and function have been observed in vitro and in vivo, and some plasticity-related pathways overlap with those implicated in ketamine (for example, mTOR signalling). Imaging studies show increased prefrontal activity acutely and persisting increases after psilocybin on some cognitive tasks; psilocybin and LSD have been reported to reduce amygdala responses to negative stimuli. Molecular and activity-marker evidence offers further correspondence: animals susceptible to learned helplessness show reduced c-fos activation across many regions (including medial prefrontal cortex and amygdala), whereas psilocybin increases c-fos activity in similar cortical and limbic regions and reduces c-fos in the DRN. Behavioural pharmacology in rodents provides mixed but suggestive results. Shao and colleagues found that in group-housed mice exposed to inescapable foot shocks, within-subject psilocybin (1 mg/kg) reduced escape failures, though between-group comparisons (psilocybin versus saline or ketamine 10 mg/kg) did not show a clear treatment effect. In a different paradigm using long-term intermittent stress in single-housed animals, 1 mg/kg psilocin did not reverse learned helplessness but did improve measures of despair-like behaviour (sucrose preference, tail suspension). Ketamine consistently reverses helplessness behaviour in multiple studies and restores stress-blunted cortical spinogenesis. Repeated LSD administration has ameliorated chronic stress–induced anxiety-like behaviours and increased cortical spinogenesis in stressed animals. In forced swim tests, both ketamine and psilocybin have produced increased escape behaviour at 1 week post-administration, with psilocybin effects reported to persist to 30 days in some studies. In humans, the extracted text reports that classical psychedelics have not been directly tested in validated learned helplessness paradigms. Human laboratory models of helplessness exist (for example, inescapable aversive tones or unsolvable puzzles) and show analogous behavioural passivity after unavoidable stress, but these paradigms suffer from limited recent replication and questions about persistence. Clinical trials have shown antidepressant effects of psilocybin, but links between those clinical outcomes and reversal of learned helplessness have not been tested.

Tiwari and colleagues interpret the assembled evidence to suggest that learned helplessness is a promising transdiagnostic mechanism to explain some therapeutic effects of classic psychedelics. They argue that the vmPFC–DRN circuit, DRN modulation, amygdala suppression, and enhancement of cortical plasticity are mechanistic points of overlap that could plausibly underlie a psychedelic-driven reversal of helplessness and the development of resilience to future stressors. The authors highlight that learned helplessness is attractive as a framework because it is replicable across species, grounded in well-described circuitry, falsifiable, and capable of linking molecular, circuit, behavioural, and subjective levels of analysis. The paper acknowledges important caveats and uncertainties. Direct causal evidence that psychedelics reverse learned helplessness is limited: only a few preclinical studies have directly tested learned helplessness paradigms with classic psychedelics, and results have been mixed and sensitive to experimental design (for example, housing conditions and timing of stress and drug administration). Mechanistic findings are sometimes apparently contradictory—for example, differing accounts of 5-HT1A versus 5-HT2A involvement in DRN modulation—and the durable changes by which psychedelics might ‘‘immunize’’ circuits against future helplessness remain unproven. Human learned-helplessness paradigms have not been applied to psychedelic interventions, and existing human models lack robust replication and clarity about persistence of effects. For future work, the authors recommend using learned helplessness paradigms across mammalian species to test behavioural and mechanistic hypotheses about psychedelics. Specific suggestions include brain-wide mapping of activity-dependent markers (for example c-fos) to compare activation patterns of susceptible versus resilient animals under psychedelic treatment, optogenetic and circuit-level manipulations to test causal roles of vmPFC–DRN pathways, and carefully designed behavioural experiments that consider timing, housing, and stressor parameters. The authors also call for characterising individual differences in susceptibility and resilience to learned helplessness to inform personalised approaches to psychedelic therapies. Overall, they present learned helplessness as a productive, testable framework that could advance mechanistic and translational understanding of psychedelic treatment effects.

The authors conclude that learned helplessness has well-elucidated neural mechanisms—principally DRN activation producing passivity and a vmPFC–DRN pathway that reverses helplessness and confers immunization—and that these mechanisms substantially overlap with known actions of classic psychedelics, which activate prefrontal cortex and can inhibit DRN activity. Given its cross-species reproducibility and multilevel specification, learned helplessness could serve as a bridge between molecular, circuit, behavioural, and clinical research on psychedelics. The paper emphasises the need to investigate individual differences in resilience and susceptibility and proposes that pursuing this model may help explain therapeutic benefits and guide more personalised psychedelic interventions.